TriNetX study links GLP-1 plus SGLT2 inhibitor to fewer kidney events in CKD
Among 32,448 matched adults with chronic kidney disease, adding a GLP-1 receptor agonist was associated with a 30% lower rate of major adverse kidney events over a median 12 months.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 26 20:00 ETSource: Diabetes, obesity & metabolism
The wire
- 01Retrospective cohort in Diabetes, Obesity & Metabolism matched 16,224 patients per arm and found MAKE HR 0.70 (95% CI 0.65-0.74), MACE HR 0.83 and all-cause mortality HR 0.55 for combination therapy.
- 02Benefits held across CKD stages and diabetes status and were larger in patients with obesity, heart failure or ischaemic heart disease, informing add-on decisions in cardiorenal care.
- 03Combination therapy was associated with more gastrointestinal symptoms, genital infections and retinopathy progression; the authors note this is observational and call for randomised trials.
From the source
Read at pubmed.ncbi.nlm.nih.govEffectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
Diabetes, obesity & metabolism · 2026 Sep 27 · Salim H, Qureshi S, Gulsin GS et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42802242/
